Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Trial Profile

A Phase 1/1b Multicenter Study To Evaluate The Humanized Anti-CD73 Antibody, CPI-006, As A Single Agent, In Combination With CPI-444, And In Combination With Pembrolizumab In Adult Subjects With Advanced Cancers

Recruiting
Phase of Trial: Phase I

Latest Information Update: 06 Feb 2019

At a glance

  • Drugs CPI 444 (Primary) ; CPI-006 (Primary) ; Pembrolizumab (Primary)
  • Indications Advanced breast cancer; Bladder cancer; Cervical cancer; Colorectal cancer; Endometrial cancer; Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma; Sarcoma; Solid tumours; Uterine cancer
  • Focus Adverse reactions
  • Sponsors Corvus Pharmaceuticals
  • Most Recent Events

    • 06 Feb 2019 According to a Corvus Pharmaceuticals media release, updated biomarker and clinical results from this study were presented at the Immuno-Oncology 360 degree conference in New York during the "Discovery & Preclinical Science Plenary"session.
    • 06 Feb 2019 Results published in the Media Release
    • 08 Jan 2019 According to a Corvus Pharmaceuticals media release, patient enrollment has been initiated in the second arm of this study. This arm is evaluating CPI-006 in combination with CPI-444 and is currently enrolling patients with non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC) and other cancers who have failed standard therapies.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top